Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
61
PHAR Quote, Financials, Valuation and Earnings
Last price:
$17.40
Seasonality move
:
6.91%
Day range:
$16.20 - $17.67
52-week range:
$7.50 - $17.86
Dividend yield:
0%
P/E ratio:
1,213.29x
P/S ratio:
3.27x
P/B ratio:
4.49x
Volume:
47.9K
Avg. volume:
19.5K
1-year change:
124.16%
Market cap:
$1.2B
Revenue:
$296.7M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 10.75% | -67.59% | $31.00 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$167.4M | $0.37 | 60.47% | -62.86% | $54.00 |
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -5.57% | -135.86% | $97.00 |
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 14.37% | -38.51% | $58.48 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$17.35 | $31.00 | $1.2B | 1,213.29x | $0.00 | 0% | 3.27x |
|
CRMD
CorMedix, Inc.
|
$10.64 | $19.00 | $838.3M | 5.18x | $0.00 | 0% | 3.58x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$40.99 | $54.00 | $3.1B | 91.43x | $0.00 | 0% | 5.25x |
|
MRUS
Merus NV
|
$96.22 | $97.00 | $7.3B | -- | $0.00 | 0% | 120.95x |
|
PRQR
ProQR Therapeutics NV
|
$2.12 | $8.88 | $223.3M | -- | $0.00 | 0% | 12.82x |
|
QURE
uniQure NV
|
$22.74 | $58.48 | $1.4B | -- | $0.00 | 0% | 77.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.243 | 0.33% | 3.27x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Pharming Group NV vs. Competitors
-
Which has Higher Returns PHAR or CRMD?
CorMedix, Inc. has a net margin of 7.71% compared to Pharming Group NV's net margin of 49.9%. Pharming Group NV's return on equity of 0.39% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About PHAR or CRMD?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 78.67%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that Pharming Group NV has higher upside potential than CorMedix, Inc., analysts believe Pharming Group NV is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 CRMDCorMedix, Inc.4 0 0 -
Is PHAR or CRMD More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock PHAR or CRMD?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or CRMD?
Pharming Group NV quarterly revenues are $96.9M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Pharming Group NV's net income of $7.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Pharming Group NV's price-to-earnings ratio is 1,213.29x while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.27x versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.27x 1,213.29x $96.9M $7.5M CRMDCorMedix, Inc.3.58x 5.18x $104.3M $108.6M
-
Which has Higher Returns PHAR or KNSA?
Kiniksa Pharmaceuticals International Plc has a net margin of 7.71% compared to Pharming Group NV's net margin of 10.19%. Pharming Group NV's return on equity of 0.39% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M -
What do Analysts Say About PHAR or KNSA?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 78.67%. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $54.00 which suggests that it could grow by 31.74%. Given that Pharming Group NV has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe Pharming Group NV is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 KNSAKiniksa Pharmaceuticals International Plc6 0 0 -
Is PHAR or KNSA More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.017, suggesting its less volatile than the S&P 500 by 98.312%.
-
Which is a Better Dividend Stock PHAR or KNSA?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or KNSA?
Pharming Group NV quarterly revenues are $96.9M, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Pharming Group NV's net income of $7.5M is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Pharming Group NV's price-to-earnings ratio is 1,213.29x while Kiniksa Pharmaceuticals International Plc's PE ratio is 91.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.27x versus 5.25x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.27x 1,213.29x $96.9M $7.5M KNSAKiniksa Pharmaceuticals International Plc5.25x 91.43x $180.9M $18.4M
-
Which has Higher Returns PHAR or MRUS?
Merus NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -786.17%. Pharming Group NV's return on equity of 0.39% beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About PHAR or MRUS?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 78.67%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.81%. Given that Pharming Group NV has higher upside potential than Merus NV, analysts believe Pharming Group NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 MRUSMerus NV2 14 0 -
Is PHAR or MRUS More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock PHAR or MRUS?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or MRUS?
Pharming Group NV quarterly revenues are $96.9M, which are larger than Merus NV quarterly revenues of $12.2M. Pharming Group NV's net income of $7.5M is higher than Merus NV's net income of -$95.5M. Notably, Pharming Group NV's price-to-earnings ratio is 1,213.29x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.27x versus 120.95x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.27x 1,213.29x $96.9M $7.5M MRUSMerus NV120.95x -- $12.2M -$95.5M
-
Which has Higher Returns PHAR or PRQR?
ProQR Therapeutics NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -381.88%. Pharming Group NV's return on equity of 0.39% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About PHAR or PRQR?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 78.67%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 318.63%. Given that ProQR Therapeutics NV has higher upside potential than Pharming Group NV, analysts believe ProQR Therapeutics NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 PRQRProQR Therapeutics NV7 0 0 -
Is PHAR or PRQR More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock PHAR or PRQR?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or PRQR?
Pharming Group NV quarterly revenues are $96.9M, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. Pharming Group NV's net income of $7.5M is higher than ProQR Therapeutics NV's net income of -$12.9M. Notably, Pharming Group NV's price-to-earnings ratio is 1,213.29x while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.27x versus 12.82x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.27x 1,213.29x $96.9M $7.5M PRQRProQR Therapeutics NV12.82x -- $3.4M -$12.9M
-
Which has Higher Returns PHAR or QURE?
uniQure NV has a net margin of 7.71% compared to Pharming Group NV's net margin of -2175.87%. Pharming Group NV's return on equity of 0.39% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital PHARPharming Group NV92.7% $0.11 $395.6M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About PHAR or QURE?
Pharming Group NV has a consensus price target of $31.00, signalling upside risk potential of 78.67%. On the other hand uniQure NV has an analysts' consensus of $58.48 which suggests that it could grow by 157.21%. Given that uniQure NV has higher upside potential than Pharming Group NV, analysts believe uniQure NV is more attractive than Pharming Group NV.
Company Buy Ratings Hold Ratings Sell Ratings PHARPharming Group NV2 0 0 QUREuniQure NV9 2 0 -
Is PHAR or QURE More Risky?
Pharming Group NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock PHAR or QURE?
Pharming Group NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharming Group NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHAR or QURE?
Pharming Group NV quarterly revenues are $96.9M, which are larger than uniQure NV quarterly revenues of $3.7M. Pharming Group NV's net income of $7.5M is higher than uniQure NV's net income of -$80.5M. Notably, Pharming Group NV's price-to-earnings ratio is 1,213.29x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharming Group NV is 3.27x versus 77.70x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHARPharming Group NV3.27x 1,213.29x $96.9M $7.5M QUREuniQure NV77.70x -- $3.7M -$80.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
